Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

This study has been completed.
Merck KGaA
Information provided by (Responsible Party):
EMD Serono Identifier:
First received: September 14, 2012
Last updated: February 11, 2016
Last verified: February 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2016
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)